Your browser doesn't support javascript.
Impact of the COVID-19 Pandemic on a Cancer Fast-Track Programme.
Martínez, M T; Moragon, S; Ortega-Morillo, B; Montón-Bueno, J; Simon, S; Roselló, S; Insa, A; Viala, A; Navarro, J; Sanmartín, A; Fluixá, C; Julve, A; Soriano, D; Buch, E; Peña, A; Franco, J; Martínez-Jabaloyas, J; Marco, J; Forner, M J; Cano, A; Silvestre, A; Teruel, A; Bermejo, B; Cervantes, A; Chirivella Gonzalez, I.
  • Martínez MT; Department of Medical Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
  • Moragon S; Department of Medical Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
  • Ortega-Morillo B; Department of Medical Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
  • Montón-Bueno J; Department of Medical Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
  • Simon S; Department of Medical Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
  • Roselló S; Department of Medical Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
  • Insa A; Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Viala A; Instituto de Salud Carlos III, CIBERONC, Madrid, Spain.
  • Navarro J; Department of Medical Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
  • Sanmartín A; Department of Medical Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
  • Fluixá C; Management Department, Hospital Clinico Universitario de Valencia, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
  • Julve A; CIBERESP (CIBER de Epidemiología y Salud Pública), Centro Nacional de Epidemiología Del Instituto de Salud Carlos III, Madrid, Spain.
  • Soriano D; Management Department, Hospital Clinico Universitario de Valencia, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain.
  • Buch E; Alfahuir Primare Care Center, Valencia, Spain.
  • Peña A; Department of Radiodiagnosis, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Franco J; Department of Radiodiagnosis, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Martínez-Jabaloyas J; Department of Surgery, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Marco J; Department of Medicine Digestive, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Forner MJ; Department of Pneumology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Cano A; Department of Urology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Silvestre A; Department of Otolaryngology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Teruel A; Department of Internal Medicine, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Bermejo B; Department of Gynaecology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Cervantes A; Department of Traumatology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
  • Chirivella Gonzalez I; Department of Haematology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain.
Cancer Control ; 29: 10732748221131000, 2022.
Article in English | MEDLINE | ID: covidwho-2117311
ABSTRACT

INTRODUCTION:

The COVID-19 pandemic has disrupted many aspects of clinical practice in oncology, particularly regarding early cancer diagnosis, sparking public health concerns that possible delays could increase the proportion of patients diagnosed at advanced stages. In 2009, a cancer fast-track program (CFP) was implemented at the Clinico-Malvarrosa Health Department in Valencia, Spain with the aim of shortening waiting times between suspected cancer symptoms, diagnosis and therapy initiation.

OBJECTIVES:

The study aimed to explore the effects of the COVID-19 pandemic on our cancer diagnosis fast-track program.

METHODS:

The program workflow (patients included and time periods) was analysed from the beginning of the state of alarm on March 16th, 2020 until March 15th, 2021. Data was compared with data from the same period of time from the year before (2019).

RESULTS:

During the pandemic year, 975 suspected cancer cases were submitted to the CFP. The number of submissions only decreased during times of highest COVID-19 incidence and stricter lockdown, and overall, referrals were slightly higher than in the previous 2 years. Cancer diagnosis was confirmed in 197 (24.1%) cases, among which 33% were urological, 23% breast, 16% gastrointestinal and 9% lung cancer. The median time from referral to specialist appointment was 13 days and diagnosis was reached at a median of 18 days. In confirmed cancer cases, treatment was started at around 30 days from time of diagnosis. In total, 61% of cancer disease was detected at early stage, 20% at locally advanced stage, and 19% at advanced stage, displaying time frames and case proportions similar to pre-pandemic years.

CONCLUSIONS:

Our program has been able to maintain normal flow and efficacy despite the challenges of the current pandemic, and has proven a reliable tool to help primary care physicians referring suspected cancer patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Lung Neoplasms Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Cancer Control Journal subject: Neoplasms Year: 2022 Document Type: Article Affiliation country: 10732748221131000

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Lung Neoplasms Type of study: Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Cancer Control Journal subject: Neoplasms Year: 2022 Document Type: Article Affiliation country: 10732748221131000